GRI Bio, Inc. (GRI) vs Nuvilex Inc. (PMCB)

GRI Bio, Inc. and Nuvilex Inc. are both Biotechnology companies. GRI Bio, Inc. and Nuvilex Inc. are of similar size ($4.9M and $4.6M). Nuvilex Inc. has negative trailing earnings, so its P/E is not meaningful; GRI Bio, Inc. trades at 0.0×. Across the 10 metrics below, Nuvilex Inc. leads on 6 and GRI Bio, Inc. on 4.

Valuation

Metric GRI PMCB Biotechnology median
P/E 0.03 n/m 7.88
P/S n/m n/m 11.47
P/B 0.36 0.17 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.74 3.67 0.74
EV/Sales n/m n/m 10.73
Earnings yield 3,640.53% (509.84%) (28.84%)
Free cash flow yield (281.76%) (224.12%) (23.03%)

Profitability

Metric GRI PMCB Biotechnology median
Gross margin 0.00% 95.64% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (142.02%) (58.04%) (57.72%)
Return on assets (113.27%) (50.43%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GRI PMCB Biotechnology median
Revenue growth (TTM) — (71.06%) 5.64%
EPS growth (last fiscal year) 92.12% (186.83%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GRI PMCB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.30 40.29 4.73
Net debt to EBITDA 0.69 5.41 0.96

Dividend

Metric GRI PMCB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GRI PMCB Biotechnology median
Market cap 4.57m 4.90m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack